Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives-Reference-Cited by-同舟云学术

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

Published:2018-05 Issue: Volume:66 Page:104-113
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Taieb Julien,Moehler Markus,Boku Narikazu,Ajani Jaffer A.,Yañez Ruiz Eduardo,Ryu Min-Hee,Guenther Silke,Chand Vikram,Bang Yung-Jue

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference84 articles.

1. Immunotherapy for gastroesophageal cancer;Goode;J Clin Med,2016

2. International Agency for Research on Cancer. GLOBOCAN 2012: cancer incidence, mortality and prevalence worldwide in 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; 2013 [accessed 05.12.17].

3. Current status of novel agents in advanced gastroesophageal adenocarcinoma;Kothari;J Gastrointest Oncol,2015

4. American Cancer Society. Key statistics for stomach cancer, https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html; 2016 [accessed 05.12.17].

5. Comprehensive molecular characterization of gastric adenocarcinoma;Cancer Genome Atlas research network;Nature,2014

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

2. Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer;World Journal of Gastroenterology;2024-06-28

3. Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review;International Journal of Molecular Sciences;2024-06-12

4. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma;Cancer Immunology, Immunotherapy;2024-06-04

5. Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer;European Journal of Medicinal Chemistry;2024-03